5-Lipoxygenase inhibition by antifungal azole derivatives: new tools for immunosuppression?

Eicosanoids. 1989;2(3):189-90.

Abstract

The effect of novel azole derivatives (itraconazole and fluconazole) on 5-lipoxygenase activity was examined using human polymorphonuclear leukocytes (PMNL) as the enzyme source. The novel imidazole derivative itraconazole proved to be a potent inhibitor (IC50 2 X 10(-6) M) of 5-lipoxygenase activity. In contrast, fluconazole, an antifungal agent with bistriazole structure, had no effect on the Ca2+ ionophore A 23187-induced formation of 5-lipoxygenase metabolites in PMNL.

MeSH terms

  • Antifungal Agents / pharmacology
  • Arachidonate Lipoxygenases / antagonists & inhibitors*
  • Fluconazole / pharmacology*
  • Humans
  • Immunosuppressive Agents
  • In Vitro Techniques
  • Itraconazole
  • Ketoconazole / analogs & derivatives*
  • Ketoconazole / pharmacology
  • Lipoxygenase Inhibitors*
  • Neutrophils / drug effects
  • Neutrophils / enzymology
  • Neutrophils / immunology

Substances

  • Antifungal Agents
  • Immunosuppressive Agents
  • Lipoxygenase Inhibitors
  • Itraconazole
  • Fluconazole
  • Arachidonate Lipoxygenases
  • Ketoconazole